Nantahala Capital Management, LLC Autolus Therapeutics PLC Transaction History

Nantahala Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.64 - $3.21 $5.61 Million - $11 Million	-3,419,610 Reduced 44.46%	4,272,203 $10.2 Million
Q1 2023 May 15, 2023	SELL	$1.75 - $2.25 $157,858 - $202,961	-90,205 Reduced 1.16%	7,691,813 $14.2 Million
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $4.47 Million - $8.39 Million	2,566,230 Added 49.2%	7,782,018 $14.8 Million
Q3 2022 Nov 10, 2022	BUY	$2.04 - $3.76 $148,783 - $274,228	72,933 Added 1.42%	5,215,788 $11.2 Million
Q2 2022 Aug 15, 2022	BUY	$2.04 - $4.68 $1.62 Million - $3.73 Million	796,528 Added 18.33%	5,142,855 $14.6 Million
Q1 2022 May 13, 2022	BUY	$3.52 - $5.46 $946,239 - $1.47 Million	268,818 Added 6.59%	4,346,327 $18.1 Million
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $5.82 Million - $7.99 Million	1,140,718 Added 38.84%	4,077,509 $21.2 Million
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $6.08 Million - $8.43 Million	1,143,291 Added 63.75%	2,936,791 $19.2 Million
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $8.57 Million - $14.3 Million	1,793,500 New	1,793,500 $11.9 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.